CytomX Therapeutics, Inc. (CTMX)
NASDAQ: CTMX · Real-Time Price · USD
3.025
-0.155 (-4.87%)
Jun 5, 2026, 1:46 PM EDT - Market open
CytomX Therapeutics Employees
CytomX Therapeutics had 69 employees as of December 31, 2025. The number of employees decreased by 52 or -42.98% compared to the previous year.
Employees
69
Change (1Y)
-52
Growth (1Y)
-42.98%
Revenue / Employee
$515,101
Profits / Employee
-$900,623
Market Cap
658.55M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 69 | -52 | -42.98% | 69 | 0 |
| Dec 31, 2024 | 121 | -1 | -0.82% | 119 | 2 |
| Dec 31, 2023 | 122 | 4 | 3.39% | 120 | 2 |
| Dec 31, 2022 | 118 | -60 | -33.71% | 116 | 2 |
| Dec 31, 2021 | 178 | 32 | 21.92% | 174 | 4 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| CorMedix | 191 |
| Allogene Therapeutics | 152 |
| Solid Biosciences | 121 |
| BridgeBio Oncology Therapeutics | 106 |
| Alto Neuroscience | 68 |
| Zevra Therapeutics | 61 |
| Oculis Holding AG | 60 |
| Candel Therapeutics | 55 |
CTMX News
- 22 hours ago - CytomX Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 2 days ago - CytomX Therapeutics expands licensing agreement with Regeneron - TheFly
- 2 days ago - CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer - GlobeNewsWire
- 15 days ago - CytomX Therapeutics to Present at Upcoming June Investor Conferences - GlobeNewsWire
- 17 days ago - CytomX Therapeutics initiated with an Outperform at Wolfe Research - TheFly
- 18 days ago - CytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs - GlobeNewsWire
- 25 days ago - CytomX Therapeutics price target lowered to $11 from $17 at H.C. Wainwright - TheFly
- 4 weeks ago - CytomX Therapeutics reports Q1 EPS (10c), consensus (11c) - TheFly